Lennard P L Gilissen

Years Active: 2021-2023
Publications (10 Years): 4

This page only lists publications with an associated author ORCID identifier.

Publications

Merve Sivridaş, Rob H Creemers, Dennis R Wong, Paul J Boekema, Tessa E H Römkens, Lennard P L Gilissen, Adriaan A van Bodegraven, Floris C Loeff, Theo Rispens, Luc J J Derijks
Therapeutic Drug Monitoring of Vedolizumab in Inflammatory Bowel Disease Patients during Maintenance Treatment-TUMMY Study. Pharmaceutics 15 (3) (2023)
Merve Sivridaş, Rob H Creemers, Dennis R Wong, Paul J Boekema, Tessa E H Römkens, Lennard P L Gilissen, Adriaan A van Bodegraven, Floris C Loeff, Theo Rispens, Luc J J Derijks
Therapeutic Drug Monitoring of Vedolizumab in Inflammatory Bowel Disease Patients during Maintenance Treatment-TUMMY Study. Pharmaceutics 15 (3) (2023)
Merve Sivridaş, Rob H Creemers, Dennis R Wong, Paul J Boekema, Tessa E H Römkens, Lennard P L Gilissen, Adriaan A van Bodegraven, Floris C Loeff, Theo Rispens, Luc J J Derijks
Therapeutic Drug Monitoring of Vedolizumab in Inflammatory Bowel Disease Patients during Maintenance Treatment-TUMMY Study. Pharmaceutics 15 (3) (2023)
Lennard P L Gilissen, Stefan G H Heinen, Lotte Rijpma-Jacobs, Erik Schoon, Ramon-Michel Schreuder, Anne-Marie Wensing, Mirjam C M van der Ende-van Loon, Johanne G Bloemen, Janneke M Stapelbroek, Arnold Stronkhorst
Neither inflammatory bowel disease nor immunosuppressants are associated with an increased risk of severe COVID-19: an observational Dutch cohort study. Clinical and experimental medicine (2021)

Lennard P L Gilissen.css-eqlu8i{font-size:small;padding-left:4px;}